The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Possible cost savings from phase 2 oncology master protocol participation as of 2018 (in million U.S. dollars)
Cost savings from participating in phase 2 oncology master protocol
This statistic depicts the possible cost savings that could be gained from participating in a phase 2 oncology master protocol as of 2018. According to the source, total cost savings could be as high as 1.6 million U.S. dollars.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Most impactful areas to clinical real-world evidence as of 2018
- Basic Statistic Number of applications for clinical trials in Denmark 2013-2021, by sponsor
- Premium Statistic Market cap of select pharma companies with strong pipeline 2017
- Basic Statistic Number of applications for clinical trials in Norway 2008-2024
- Basic Statistic Clinical trials due to COVID-19 read out March 2020 worldwide, by stage
- Premium Statistic Clinical trials initiated worldwide 2018-2024
- Basic Statistic Clinical trials initiated worldwide 2018-2024, by trial phase
- Basic Statistic Clinical drug trials started worldwide 2018-2023, by key therapeutic area
- Basic Statistic Drugs in R&D pipeline worldwide 2025-2026, by phase of development
- Premium Statistic ATMP trials classification share by disease and development phase globally 2016
About the region
10
- Premium Statistic Cell therapy studies being conducted globally as of 2018, by region
- Basic Statistic Share of connected medical devices produced in 5 years as of 2018
- Basic Statistic Share of cell therapy studies being conducted globally as of 2018, by region
- Basic Statistic Number of cell therapies in development by strategy 2019-2021
- Basic Statistic Number of cellular immunotherapy pipeline globally by type 2020-2021
- Basic Statistic Cell therapy companies investment 2017-2021
- Basic Statistic Orphan drug sales worldwide by therapy category 2030
- Basic Statistic Alzheimer's drugs in development in 2019, by clinical trial phase
- Basic Statistic Indication expansions and new products drug pipeline worldwide 2020
- Premium Statistic Share of active trials for Alzheimer's Disease pipeline 2022, by product type
Selected statistics
10
- Premium Statistic IQVIA employee number 2014-2024
- Premium Statistic R&D spending growth worldwide on pharmaceuticals 2019-2032
- Premium Statistic Merck & Co. R&D expenditure 2006-2025
- Basic Statistic Top therapeutic categories worldwide 2026, by number of R&D products
- Premium Statistic Number of drugs in the R&D pipeline worldwide 2001-2026
- Basic Statistic Share of clinical drug trials started in Europe 2012-2022, by region
- Premium Statistic Top pharma companies worldwide 2026, by size of R&D pipeline
- Premium Statistic Distribution of pharmaceutical R&D companies by region 2025 vs. 2026
- Basic Statistic Expected acquisitions of biopharma companies by type of asset 2021
- Basic Statistic Global number of life sciences sector deals 2013-2021
Other regions
10
- Basic Statistic Usage rate of top drug classes prescribed to seniors in Canada by age 2021
- Premium Statistic Number of medicines in development for heart disease and stroke by type 2018
- Premium Statistic Novel pain drug clinical trials success rates U.S. 2006-2015, by phase
- Premium Statistic Clinical trial starts for new obesity drugs U.S. 2008-2017
- Premium Statistic U.S. states with large employment in drugs and pharmaceuticals 2023
- Premium Statistic Type 2 diabetes clinical trial success rates U.S. 2006-2015, by phase and indication
- Premium Statistic Type 2 diabetes clinical pipeline in the U.S. in 2018, by type and phase
- Basic Statistic Number of applications for clinical trials in Norway 2008-2024, by type of actor
- Basic Statistic Expedited drug approvals by firms from California 2014-2019
- Basic Statistic Cannabinoid clinical trials registered in the U.S. in 2018, by company
Related statistics
10
- Basic Statistic Major biotech IPOs 2025
- Basic Statistic Top global orphan drugs by revenue 2018
- Basic Statistic Technologies to improve patient experiences in life sciences organizations 2018
- Basic Statistic Pharmaceutical companies with Alzheimer's drugs in development 2019
- Basic Statistic Number of active trials in Alzheimer's Disease pipeline 2022, by product type
- Basic Statistic Key technologies in Alzheimer's Disease clinical trials 2021
- Basic Statistic Indications in clinical trials for cell and gene therapies worldwide 2022
- Basic Statistic Key indications in oncology pipeline worldwide 2023
- Basic Statistic Mechanism of action in oncology pipeline worldwide 2023
- Premium Statistic Mechanism of action in obesity R&D pipeline worldwide 2024
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Deloitte. (January 22, 2019). Possible cost savings from phase 2 oncology master protocol participation as of 2018 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 25, 2026, from /statistics/973374/cost-savings-phase-2-oncology-master-protocol/
Deloitte. "Possible cost savings from phase 2 oncology master protocol participation as of 2018 (in million U.S. dollars)." Chart. January 22, 2019. ÌÇÐÄÆƽâ°æ. Accessed July 25, 2026. /statistics/973374/cost-savings-phase-2-oncology-master-protocol/
Deloitte. (2019). Possible cost savings from phase 2 oncology master protocol participation as of 2018 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 25, 2026. /statistics/973374/cost-savings-phase-2-oncology-master-protocol/
Deloitte. "Possible Cost Savings from Phase 2 Oncology Master Protocol Participation as of 2018 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 22 Jan 2019, /statistics/973374/cost-savings-phase-2-oncology-master-protocol/
Deloitte, Possible cost savings from phase 2 oncology master protocol participation as of 2018 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/973374/cost-savings-phase-2-oncology-master-protocol/ (last visited July 25, 2026)
Possible cost savings from phase 2 oncology master protocol participation as of 2018 (in million U.S. dollars) [Graph], Deloitte, January 22, 2019. [Online]. Available: /statistics/973374/cost-savings-phase-2-oncology-master-protocol/
Advertisement